Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout

Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.